Singapore medtech firm unveils shelf-stable synthetic skin product

Singapore-based medtech start-up Bioactivx has introduced Bioactiv Matrix, a synthetic skin substitute engineered to operate without requiring refrigeration or other specialised storage conditions. The innovation addresses a significant limitation of existing skin replacement products, which typically demand controlled temperature environments that can be difficult to maintain in field settings.

The shelf-stable formulation opens new possibilities for deploying the product in challenging environments where maintaining cold-chain logistics proves impractical or impossible. Disaster zones, remote medical facilities, and resource-constrained settings stand to benefit from improved accessibility to advanced wound care solutions.

The development reflects growing momentum in Singapore's medtech sector, where start-ups are increasingly focusing on practical innovations that address real-world healthcare delivery challenges. By removing dependency on specialised storage infrastructure, Bioactivx has created a product with broader geographical reach and deployment flexibility than conventional alternatives.

The launch comes as global demand for advanced wound care and skin substitutes continues to rise, driven by increasing incidence of burn injuries, chronic wounds, and surgical applications. Bioactiv Matrix positions itself as a practical solution for scenarios where conventional products face logistical constraints.